IDEXX LaboratoriesXTER:IX1 96 Gross Margin % is 63.35% as of Mar. 2026, which is 8% above its 10-year median of 58.40. GuruFocus rates XTER:IX1 with a GF Score™ of 96/100 and a GF Value™ of €559.26. Among 194 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 65.98% on this metric.
The historical rank and industry rank for IDEXX Laboratories's Gross Margin % or its related term are showing as below:
XTER:IX1'
s Gross Margin % Range Over the Past 10 Years
Min: 54.94 Med: 58.4 Max: 62.05
Current: 62.05
During the past 13 years, the highestGross Margin % of IDEXX Laboratories was 62.05%. The lowest was 54.94%. And the median was 58.40%.
XTER:IX1's Gross Margin % is ranked better than 65.98% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.45
vs XTER:IX1: 62.05
IDEXX Laboratories had a gross margin of 63.35% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for IDEXX Laboratories was 1.30% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
IDEXX Laboratories had a gross margin of 63.35% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
IDEXX Laboratories Gross Margin % Related Terms
IDEXX Laboratories Gross Margin % Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:IX1 vs A, WAT, NTRA: Gross Margin % Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Gross Margin % distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
IDEXX Laboratories (XTER:IX1) has a Gross Margin % of 63.35% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on IDEXX Laboratories and its competitors. This is near median its historical median of 58.40. Over the past decade, IDEXX Laboratories' Gross Margin % has ranged from 54.94 to 62.05. According to the industry distribution chart, IDEXX Laboratories ranks #66 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 34%.
Is IDEXX Laboratories' Gross Margin % too high?
IDEXX Laboratories' current Gross Margin % of 63.35% is near median its 10-year median of 58.40. Over the past 10 years, this metric has ranged from a low of 54.94 to a high of 62.05. The Medical Diagnostics & Research industry median Gross Margin % is 50.45. IDEXX Laboratories' value of 63.35% is 25.6% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #66 out of 194 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, IDEXX Laboratories has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Gross Margin % compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #66 out of 194 companies for Gross Margin %. This puts IDEXX Laboratories in the upper half of its industry. The industry median Gross Margin % is 50.45. IDEXX Laboratories' value of 63.35% is 25.6% above this benchmark. Historically, IDEXX Laboratories' own Gross Margin % has ranged from 54.94 to 62.05 over the past decade. While the company's 10-year median is 58.40 vs. the industry median of 50.45, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.45, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current Gross Margin % of 63.35% is 25.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current Gross Margin % is 63.35%, which is near median its own 10-year median of 58.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
IDEXX Laboratories (XTER:IX1) has a current Gross Margin % of 63.35%. The stock's GF Value™ is €559.26, compared to a current price of €488.90 — trading 12.6% below its estimated fair value. The current Gross Margin % is 63.35%, which is near median its 10-year median of 58.40 and 25.6% above the Medical Diagnostics & Research industry median of 50.45. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For IDEXX Laboratories (XTER:IX1), the current Gross Margin % is 63.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (XTER:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €488.90 is trading 12.6% below its estimated GF Value™ of €559.26.
Key valuation signals for XTER:IX1:
Gross Margin %: 63.35% (near median its 10-year median of 58.40)
GF Value™: €559.26 vs. price of €488.90 (12.6% below fair value)
Industry Position: 25.6% above the Medical Diagnostics & Research median (#66 of 194)
No single metric tells the full story. See the XTER:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for XTER:IX1
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:IX1 has been successfully added to your 
